Sight Sciences, Inc. is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.
Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model. Its clinical programs have explored both standalone and adjunctive uses of its platforms, seeking to expand indications in glaucoma management and ocular surface disease. The company continues to invest in iterative improvements and new treatment modalities built upon its core thermal and micro-invasive glaucoma surgery (MIGS) technologies.
Headquartered in Menlo Park, California, Sight Sciences distributes its products across the United States and has established partnerships to serve markets in Canada, Europe and Australia. The company supports its customers with training programs, surgical support services and a dedicated clinical affairs team to gather real-world evidence and refine procedural protocols.
Leadership at Sight Sciences includes President and Chief Executive Officer Gregg Prentice, who brings deep experience in medical device commercialization, and a management team with expertise in ophthalmology, regulatory affairs and commercial operations. The company’s board and executive ranks blend industry veterans with academic researchers, underscoring its commitment to advancing eye care through innovation.
AI Generated. May Contain Errors.
